Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome

Xiao Li†, Feng Xu†, Zheng Zhang, Juan Guo, Qi He, Lu-Xi Song, Dong Wu, Li-Yu Zhou, Ji-Ying Su, Chao Xiao, Chun-Kang Chang and Ling-Yun Wu*

Abstract

Background: BCOR (BCL6 corepressor) is an epigenetic regulator gene involved in the specification of cell differentiation and body structure development. Recurrent somatic BCOR mutations have been identified in myelodysplastic syndrome (MDS). However, the clinical impact of BCOR mutations on MDS prognosis is controversial and the response of hypomethylating agents in MDS with BCOR mutations (BCORMUT) remains unknown.

Results: Among 676 MDS patients, 43 patients (6.4%) harbored BCOR mutations. A higher frequency of BCOR mutations (8.7%) was investigated in patients with normal chromosome, compared to 4.2% in patients with abnormal karyotype (p = 0.040). Compared to the BCORWT patients, the BCORMUT patients showed a higher ratio of refractory anemia with excess blasts subset (p = 0.008). The most common comutations with BCOR genes were ASXL1 (p = 0.002), DNMT3A (p = 0.114) and TET2 (p = 0.148). When the hierarchy of somatic mutations was analyzed, BCOR mutations were below the known initial mutations (ASXL1 or TET2) but were above U2AF1 mutations. Transformation-free survival was significantly shorter in BCORMUT patients than that in BCORWT patients (16 vs. 35 months; p = 0.035).

RNA-sequencing was performed in bone marrow mononuclear cells from BCORMUT and BCORWT patients and revealed 2030 upregulated and 772 downregulated genes. Importantly, HOXA6, HOXB7, and HOXB9 were significantly over-expressed in BCORMUT patients, compared to BCORWT patients. Eight of 14 BCORMUT patients (57.1%) achieved complete remission (CR) with decitabine treatment, which was much higher than that in BCORWT patients (28.7%, p = 0.036). Paired sequencing results (before and after decitabine) showed three of 6 CR patients lost the mutated BCOR. The median survival of CR patients with a BCORMUT was 40 months, which was significantly longer than that in patients with BCORWT (20 months, p = 0.036). Notably, prolonged survival was observed in three BCORMUT CR patients even without any subsequent therapies.

Conclusions: BCOR mutations occur more frequently in CN MDS patients, predicting higher risk of leukemia transformation. BCORMUT patients showed a better response to decitabine and achieved longer post-CR survival.

Keywords: Myelodysplastic syndrome, BCL6 corepressor, Decitabine

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
high rate of apoptosis and eventual symptoms related to bone marrow failure [1]. Cellular differentiation is an epigenetic process that requires specific and highly ordered DNA methylation and histone modification programs. Aberrant differentiation in MDS can often be traced to abnormal DNA methylation as well as mutations in genes that regulate epigenetic programs involved in DNA methylation or histone modification control [1].

The BCL6 corepressor (BCOR) is located on chromosome X, in the Xp11.4 locus, taking part in a specific type of polycomb repressive complex (PRC) 1.1 that mediates transcriptional repression through epigenetic modifications of histones. BCOR also functions as an interacting corepressor of BCL-6 that enhances BCL-6-mediated transcriptional repression. Therefore, constitutional inactivating mutations of this gene have been implicated in many solid tumors and hematopoietic malignancies, including leukemia and MDS (perturbing myeloid differentiation and promoting leukemogenesis) [2, 3].

The diversity of somatically mutated genes reflects a variety of pathogenic mechanisms in MDS [4–7]. Among the various somatic mutations during the development of MDS, BCOR mutations were reported in detail until 2013 [8] and may carry some prognostic value [8–10]. BCOR mutations appeared to occur easily in MDS patients with normal chromosomes; BCOR mutations were associated with DNMT3A or RUNX1 mutations and were independently associated with worse overall survival (OS). However, there are few reported cases, and the response status of BCORMUT patients towards classical hypomethylating agents (HMAs) is still lacking.

In this assay, the similarities and differences of the BCOR mutation features of a large cohort (676 total patients) of Chinese MDS patients were analyzed and compared to the results in the existing literature. More importantly, we analyzed for the first time the response of a group of 14 BCORMUT patients to the standard decitabine treatment. Furthermore, the possible mechanism of BCOR mutation in the pathogenesis of MDS was explored primarily.

Methods

Subjects
A cohort of 676 patients was included continuously in this study. All the patients were diagnosed in our own center between January 2009 and March 2019. According to the World Health Organization (WHO) and French–American–British classification (FAB) [11], this cohort included 646 MDS patients and 30 chronic myelomonocytic leukemia (CMML) patients. Clinical and hemato logic data were recorded following informed consent in accordance with the Declaration of Helsinki; this study was approved by hospital review boards of the Shanghai Jiao Tong University Affiliated Sixth People’s Hospital.

Targeted gene sequencing
Genomic DNA (gDNA) was extracted from bone marrow mononuclear cells. The purity (OD260/280 > 1.8) and concentration (50 ng per µl) of the gDNA met the sequencing requirements. We used a gene panel to amplify 39 MDS-related target genes: ANKRD11, ASXL1, BCOR, CBL, CEBPA, CALR, DHX9, DNMT3A, ETV6, EZH2, FLT3, GATA2, IDH1, IDH2, ITIH3, JAK2, KIF20B, c-KIT, KRAS, MPL, NF1, NPM1, N-RAS, PHF6, PTEN, PTEN, ROBO1, ROBO2, RUNX1, SETBP1, SF3B1, RSF2, STAG2, TET2, TP53, U2AF1, UPF3A, WT1 and ZRSR2. These targeted genes were sequenced for mutations using MiSeq sequencing (Illumina, San Diego, CA, USA). To identify mutations in the highlighted genes, we designed PCR primers using the primer XL pipeline. A total of 1164 oligonucleotide pairs were produced. The amplification reactions were conducted using an ABI 2720 Thermal Cycler. The PCR products were used to generate a library for further detection, and the DNA adapter-ligated and adapter-indexed fragments from 10 libraries were then pooled and hybridized. After hybridization of the sequencing primers, base incorporation was performed in a single lane using a MiSeq Benchtop Sequencer following the manufacturer’s standard cluster generation and sequencing protocols; in total, 250 cycles of sequencing per read were used to generate paired-end reads, and included 250 bp at each end and 8 bp of the index tag.

RNA sequencing and analysis of integrative network
Total RNA was extracted with TRIzol reagent (Invitrogen, CA, USA) following the vendor’s process from bone marrow mononuclear cells of three MDS patients harboring BCOR mutations and three patients with BCOR wild type. RNA sequencing was performed on the Illumina Hiseq 2500 (Illumina, USA). R software package was adopted for processing the differentially expressed genes (DEGs). Pathway enrichment analyses of the dysregulated genes were also carried out. Our study employed the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) online database to identify the interactions of DEGs.

Decitabine therapy
A total of 195 of the 676 MDS patients accepted decitabine treatment (DACOGEN; JANSSEN PHARMA CEUTICA), and their responses and outcomes were retrospectively analyzed. Enrolment (beginning of decitabine therapy for each individual) occurred between September 2009 and January 2019. All 195 patients received
20 mg/m² decitabine intravenously for 5 consecutive days every 4–6 weeks. The median therapy course was four cycles. Among these patients, fourteen harbored BCOR mutations. The median number of decitabine therapy cycles for the 14 BCORMUT patients was also four. Response to treatment was assessed using the International Working Group (IWG) Response Criteria for MDS, which was revised in 2006 [12].

Statistical analysis
Statistical analyses were conducted using SPSS software, version 19.0. The association of mutations with clinical characteristics was analyzed via the χ² test. Comparisons of two independent samples were assessed using two-tailed Student’s t test. OS was defined as the time from the date of diagnosis to death or survival at the last follow-up (censored). Acute myeloid leukemia (AML)-free survival was calculated from the time of diagnosis to AML progression at the last follow-up (censored). Cumulative incidence of AML transformation was documented. Kaplan–Meier analysis was used to evaluate the time of survival and time of transformation to AML. All p values were based on 2-sided tests, and p values less than 0.05 were considered statistically significant.

Results
Mutation landscape of BCOR
Among the 676 patients, a total of 43 patients (6.4%) displayed BCOR gene mutations. Twenty-five of the 43 (58.1%) mutations involved exon 4, and ten of the 25 patients harbored a P483L mutation. Nineteen (44.2%) of the 43 mutations gave rise to a truncated BCOR gene [including 16 patients (37.2%) with a frameshift mutation] (Fig. 1a). Six of the 43 patients presented isolated BCOR mutations, and all the remaining BCOR mutations coexisted with mutations in other genes, most significantly including ASXL1 (13/43 BCORMUT patients, 30.2%, vs. 84/633 BCORWT patients, 13.3%; p = 0.002), DNMT3A (8/43 BCORMUT patients, 18.6%, vs. 68/633 BCORWT patients, 10.7%; p = 0.114), and TET2 (10/43 BCORMUT patients, 23.3%, vs. 95/633 BCORWT patients, 15.0%; p = 0.148). Mutation of RUNX1 (reported by Frederick Damm [7]) to be the most common comutation was inconspicuous in this assay (7/43 BCORMUT patients, 16.3%, vs. 95/633 BCORWT patients, 15.0%; p = 0.822) (Fig. 1b). To obtain insights into the hierarchy of somatic mutations in BCORMUT patients, we investigated all identified comutations in bulky BM cells from 14 female BCORMUT patients. Patients with isolated BCOR mutations were not included because of the lack of co-mutated genes. Male patients were also ruled out from this analysis for their mutated BCOR variant allele frequency (VAF) appeared to be bi-allele-alike, because of the special location of BCOR in chromosome X. BCOR mutations emerged in three styles (Fig. 2): First, the VAF of BCOR mutations was lower than that of the coexisting mutations, suggesting that the BCOR mutations were not disease-initiating events (especially comutated with ASXL1 and TET2) (Fig. 2a, b). Second, BCORMUT mutations were parallel with other mutations (Fig. 2c, d). Third, BCOR mutations presented as earlier events than some of the other mutations (such as in U2AF1) (Fig. 2e, f).

Clinical phenotypes of BCORMUT patients
Compared to BCORWT patients, the 43 BCORMUT patients showed the following features: much higher recurring frequency in patients with normal chromosome (NC) (31/43 BCORMUT patients vs. 355/633 BCORWT patients, p = 0.040); higher refractory anemia with excess blasts (RAEB) subset ratio (p = 0.008); and tending to have more ≥ 1.5 of international prognostic scoring system (IPSS) scoring (p = 0.093) (Table 1).

Prognostic impact of BCOR mutations
The prognostic impact of BCOR mutations was evaluated. The median follow-up duration was 21.5 months. Although insignificant, in univariate analysis, a higher cumulative AML transformation rate occurred in BCORMUT patients (25.6% of the BCORMUT patients vs. 15.3% of the BCORWT patients; p = 0.076) (Table 1), and a relatively shorter OS was also observed in this BCORMUT subset (32 months for BCORMUT patients vs. 36 months for BCORWT patients; p = 0.214) (Fig. 3a). Notably, transformation-free survival (TFS) was significantly shorter in BCORMUT patients than in BCORWT patients (16 vs. 35 months; p = 0.035) (Table 1 and Fig. 3b).

Dynamics of BCOR and concurrence gene mutations during AML transformation
Serial BM targeted gene sequencing was performed in six patients with MDS harboring BCOR mutations before and after AML transformation. The molecular changes involved in the transformation of MDS to AML showed two patterns of clonal evolution. The first pattern was obtaining new gene mutations (transformation-related mutations) based on BCOR mutation, involving tumor signaling molecules, transcription factors or tumor suppressor genes. The second pattern was that the VAF of existing transformation-related gene mutations increased with time. Four of six patients showed as the first pattern. (Additional file 1: Fig. S1A–D. The VAF of BCOR mutation and other concurrence mutated genes were showed in red and green bar, respectively. The black bar showed the new gene mutations obtained in the process of AML transformation). Two of six patients presented as the second pattern of clonal evolution (Additional file 1: Fig.
Fig. 1  BCOR mutations in 43 MDS patients.  

**A** Localization of mutations identified in the BCOR gene. Each mutation is shown with an arrow. Exons of the BCOR gene are shown in colored boxes as indicated.

**B** Co-occurrence of BCOR mutations with other gene mutations studied in 43 MDS patients. The intensity of the color indicates VAF of the gene mutations.
Fig. 2. Repartitioning of BCOR mutations and other mutations. For each gene, the percentage represents the estimated percentage of cells carrying the unique mutation. Panels a and b show examples of lower VAFs for BCOR mutations than other co-mutated genes (such as ASXL1 or TET2) in 2 patients. Panels c and d show BCOR mutations that are parallel with other mutations (DNMT3A or IDH2 mutations). In panels e and f, BCOR mutations presented as earlier events than other mutations (such as U2AF1 mutations). PN presented patient number in Additional file 1: Table S1.

Table 1. Comparison of clinical parameters between BCORMUT and BCORWT patients

| Characteristics                          | BCOR mutated (n = 43) | BCOR wild-type (n = 633) | p     |
|-----------------------------------------|-----------------------|--------------------------|-------|
| Age (mean) (year)                       | 55.8                  | 55.9                     | 0.970 |
| Sex (M/F) (no) (ratio)                  | 24/19 (1.3)           | 371/262 (1.4)            | 0.719 |
| Normal chromosomes (n) (%)              | 31/43 (72.1)          | 355/633 (56.1)           | 0.040 |
| RAEB (1 + 2) (n) (%)                    | 23/43 (53.5)          | 174/633 (27.5)           | 0.008 |
| IPSS ≥ 1.5 (n) (%)                      | 15/43 (34.9)          | 149/633 (23.5)           | 0.093 |
| AML transformation ratio (n) (%)        | 11/43 (25.6)          | 97/633 (15.3)            | 0.076 |
| Median overall survival (m)             | 32                    | 36                       | 0.214 |
| AML free survival (m)                   | 16                    | 35                       | 0.035 |

The p value less than 0.05 is expressed in italics, suggesting a statistical difference.
S1E and F. The black bar showed existing transformation-related mutations increased with time).

BCOR mutation affects gene expression profiles of marrow cells

To understand how the BCOR mutation promotes MDS, we next compared independent RNA samples of bone marrow mononuclear cells (MNC) from patients with BCOR mutation and wild type using RNA-sequencing (RNA-seq). RNA-seq data revealed 2802 differentially expressed genes (DEGs), including 2030 upregulated and 772 downregulated genes (fold changes (FC) cut-off of 35 1.5; \( p < 0.05 \)) (see Additional file 2). Through RNA-seq of three pairs of independent RNA samples from bone marrow MNC, we determined the transcriptome landscape and identified the potential core genes based on hierarchical clustering analysis. The results of hierarchical clustering (Fig. 4a) suggested that the mRNA expression patterns were distinguishable between the BCORMUT and BCORWT cases. GO analyses covered three domains: biological process, cellular component and molecular function. The top 10 enriched GO terms in biological process, cellular component, and molecular function were shown in Fig. 4c. The results of KEGG pathway analysis are presented in Fig. 4b. The genes of differentially expressed were mainly associated with NF-KB pathway and MAPK signal pathway, etc. Importantly, HOX group genes including HOXA6, HOXB7 and HOXB9 were significantly over-expressed in patients harboring BCOR mutations, compared to BCOR wild type patients (Fig. 4d).

Treatment response of BCORMUT patients to decitabine

A total of 14 BCORMUT patients accepted the decitabine treatment protocol. The baseline characteristics did not differ substantially between patients with BCORMUT and BCORWT (Table 2). The median cycles of decitabine therapy between the two groups was both four \( (p = 0.411, \) Table 2). Eight of the 14 patients achieved complete remission (CR) (57.1%), which was much higher than that in patients without BCOR mutations (52 of 181 patients, 28.7%) \( (p = 0.036) \). Three BCORMUT patients achieved marrow CR (mCR) or mCR with hematological improvement (HI). The remaining 3 patients showed no response to decitabine (Table 3). When paired sequencing results (before and after decitabine) (six sets of sequencing results were available from the 8 patients who achieved CR) were analyzed, three patients showed a loss of the mutated BCOR, two showed a decrease in the VAF of mutated BCOR, and only one showed an unchanged BCOR mutation. In contrast, the three patients without a CR (non-CR) for whom paired sequencing results were available had an unchanged or increased VAF of mutated BCOR (Fig. 5a).

We hope to find a special mutated locus for BCOR or some special concomitant mutations that may play roles in good or poor responses to decitabine for these 14 patients. Table 3 shows that patients with the mutation of P483L in BCOR on exon 4 (No. 12 and 14) did not have a response to decitabine. Among the 8 patients who achieve CR, three showed coexisting ASXL1 mutations (No. 4, 7 and 11) (Table 3).

In addition to a higher response, the median survival of CR patients with a BCORMUT was 40 months, which was significantly longer than that in patients without a BCOR mutation (20 months, \( p = 0.036 \)) (Fig. 5b). Notably, prolonged survival (not accompanied with any relapse signs) was observed in three BCORMUT CR patients even without any subsequent therapies after receiving 3–5 cycles of decitabine (Nos. 3, 4 and 6 in Fig. 5c). The other CR patient, who accepted only 2 courses of decitabine or
dose-reduced cytarabine-containing chemotherapy when the disease showed early relapse, has survived for 73 months (No. 1 in Fig. 5c).

**Discussion**

In our assay, BCOR mutations occurred in 6.4% of MDS patients (including CMML) (forty-three out of 676 patients), which is similar to the data reported by Frederik Damm et al. [8] (4.7% mutation rate in 408 MDS/CMML patients). Similarly, our assay identified that 44.2% of patients had truncating mutations (including 37.2% with frameshift mutations and 7% with other inactivating mutations), supporting the theory that BCOR mutations can be an independent pathogenic factor [8]. In addition, as referred to by several previous reports [13–15], our results showed, among the 43 patients with BCOR mutations, 71.2% of the individuals possessed normal chromosomes ($p=0.040$ when compared
to those without BCOR mutations). Interestingly, we found that BCOR mutations were frequently associated with mutations in ASXL1/DNMT3A and TET2 but not in RUNX1 ($p = 0.822$) (Fig. 1b); the $p$ value for the association between BCOR and RUNX1 mutations was 0.002 as reported by Frederik Damm et al. [8], which was not similar to that for ASXL1/DNMT3A and TET2, which play initial roles in the origins of MDS [16] and also not similar to U2AF1/RUNX1 and TP53, which are linked with unique abnormal chromosomes [17–19] (trisomy 8; chromosome 7 involvement; and complex karyotypes). BCOR mutations appear to be located between the MDS origin-related mutations and MDS phenotype-/transformation-related mutations (Fig. 2), as can be seen from our hierarchical analysis of somatic mutations. For the most part, BCOR mutations occurred as

### Table 2 Characteristics of patients with BCORMUT or BCORWT received decitabine therapy

| Characteristics                  | BCORWT ($n = 181$) | BCORMUT ($n = 14$) | $p$ value |
|----------------------------------|--------------------|--------------------|-----------|
| Age, median (range), year        | 62 (17–85)         | 62 (23–80)         | 0.558     |
| Gender, male:female, n (%)       | 120:61 (66:34)     | 7:7 (50:50)        | 0.250     |
| WHO/FAB classification, n (%)    |                    |                    | 0.891     |
| RCMD                             | 47 (26.0)          | 3 (21.4)           |           |
| RAEB-1                           | 57 (31.5)          | 3 (21.4)           |           |
| RAEB-2                           | 39 (21.5)          | 5 (35.7)           |           |
| RAEB-t                           | 12 (6.6)           | 1 (7.1)            |           |
| CMML-1                           | 17 (9.4)           | 1 (7.1)            |           |
| CMML-2                           | 9 (5.0)            | 1 (7.1)            |           |
| IPSS risk, n (%)                 |                    |                    | 0.858     |
| Intermediate-1                   | 84 (46.4)          | 7 (50.0)           |           |
| Intermediate-2                   | 77 (42.5)          | 5 (35.7)           |           |
| High                             | 20 (11.1)          | 2 (14.3)           |           |
| Cytogenetic risk group, n (%)    |                    |                    |           |
| Good                             | 108 (59.7)         | 12 (85.7)          | 0.072     |
| Intermediate                     | 31 (17.1)          | 2 (14.3)           |           |
| Poor                             | 42 (23.2)          | 0                  |           |
| Decitabine cycles, median (range), n | 4 (1–11)         | 4 (2–7)            | 0.411     |

### Table 3 Gene mutation features of 14 BCORMUT patients who accepted decitabine induction

| Case no | Class     | Cycles* | Response | BCOR mutations (VAF) | Concomitant mutations |
|---------|-----------|---------|----------|----------------------|-----------------------|
| 1       | RAEB-t    | 2       | CR       | BCOR/4/C925Y (51%)   | DHX9; WT1             |
| 2       | RAEB1     | 6       | CR       | BCOR/11/K1452X (60%) | DNMT3A; ROBO1; STAG2 |
| 3       | RAEB2     | 4       | CR       | BCOR/8/R1323W (50%)  | NPM1                  |
| 4       | CMML1     | 3       | CR       | BCOR/8/K1339N (33%)  | ASXL1; MPL; TET2; UPF3A |
| 5       | RAEB1     | 4       | mCR+Hi   | BCOR/4/A619fs (16%)  | PHF6; RUNX1; TET2    |
| 6       | RCMD      | 3       | CR       | BCOR/4/Y361fs (85%)  | NRAS; ROBO1; RUNX1; U2AF1 |
| 7       | RCMD      | 4       | CR       | BCOR/12/R1547* (49%) | ASXL1; RUNX1; SRSF2 |
| 8       | RAEB1     | 4       | mCR      | BCOR/4/p819-819del (74%) | DNMT3A; IDH2; ROBO1; RUNX1 |
| 9       | RAEB2     | 4       | CR       | BCOR/7/R1165X (29%)/11/C4326+1C>A (56%) | CEBPA; DNMT3A; RUNX1; STAG2; TET2; U2AF1 |
| 10      | RAEB2     | 4       | NR       | BCOR/7/F1101fs (65%) | ITIH3                |
| 11      | RAEB2     | 4       | CR       | BCOR/4/V912fs (32%)  | ASXL1; STAG2         |
| 12      | RCMD      | 2       | NR       | BCOR/4/P483L (48%)   | DHX9; EZH2; IDH1; U2AF1 |
| 13      | RAEB2     | 4       | mCR+Hi   | BCOR/4/T738fs (46%)  | EZH2; MPL; RUNX1     |
| 14      | CMML2     | 2       | NR       | BCOR/4/P483L (100%)  | None                 |

*The induced decitabine cycles number means the course number of continuously accepted decitabine treatment (the durations between courses did not exceed 30 days); For the CR achieved patients with less than 4 induced courses. (No. 1, 4 and 6), the patients rejected continuously decitabine usage by themselves.
later events following ASXL1 or TET2 mutation (Fig. 2a, b). In another condition, BCOR mutations appeared as an earlier event, especially when comutated with U2AF1 (Fig. 2e, f). Occasionally, BCOR mutations coemerged with other mutations (such as DNMT3A or IDH2) as co-origins of MDS (Fig. 2c, d). Deeper functional studies are necessary to explore the role that BCOR mutation plays during MDS development.

RNA-sequencing results showed that HOX family genes including HOXA6, HOXB7 and HOXB9 were significantly over-expressed in patients with BCORMUT, compared to BCORWT patients. BCOR takes part into one specific type of polycomb repressive complex PRC1.1 that mediates transcriptional repression through epigenetic modifications of histones by adding an ubiquitin to histone H2A at lysine 119. This process (among others) leads to a silencing of HOX gene clusters [20] and mediates transcriptional repression. Loss of function mutation in BCOR results in the transcriptional activation of targeted genes. In the current study, HOXA6, HOXB7 and HOXB9 increased in patients with BCORMUT, which indicated HOXA6, HOXB7 and HOXB9 maybe the targeted molecular of BCOR mutation in MDS. Subsequent studies will be needed to confirm HOX genes as target of BCOR mutations mediated in leukemia transformation of MDS.

According to the literature, BCOR mutations usually predict poor prognosis [9, 10]. In our assay, 43 BCORMUT patients presented poor clinical features as a higher ratio of patients with higher IPSS scores \((\geq 1.5)\) \((p = 0.093)\).
and a higher risk of MDS in the RAEB subset \( (p = 0.001) \) (Table 1). Though insignificantly, BCOR\textsuperscript{MUT} patients showed a higher ratio of AML transformation and a shorter OS time than those with BCOR\textsuperscript{WT} (see Table 1). Importantly, BCOR\textsuperscript{MUT} patients presented significantly shorter AML-free survival (16 vs. 35 months; \( p = 0.035 \)). The high frequency of the RAEB subset of BCOR\textsuperscript{MUT} patients may cause more AML transformation as well as shorter TFS and OS. The reason for the insignificant difference of OS when compared to controls may come from the good response of some BCOR\textsuperscript{MUT} patients to decitabine therapy as described below.

The dynamic analysis of gene mutations in patients who transformed to AML showed that there were two patterns of clonal evolution, one was obtaining new gene mutation based on BCOR mutations, and the other was that the VAF of other genes that concurrence with BCOR mutations increased significantly. It hinted that BCOR mutations itself may not lead to direct leukemic transformation of clonal cells, but on the basis of BCOR mutation, clonal cells have a disposition to obtain other leukemic transformation related gene mutations, or lead to further accumulation of other leukemic transformation genes, which lead to drive MDS to transform to AML.

It is well known that the response duration achieved for MDS patients by decitabine was only approximately 6–24 months despite regular subsequent treatments, resulting in only a median OS of 18 months [21, 22]. And Patients who do not respond to HMAs, or those in whom the disease progresses after an initial response, have a poor outcome [23, 24]. Under this premise, HMAs plus other drugs [25–27] (with different mechanisms) may be one of the ways to achieve a longer survival rate. In addition, looking for some gene mutations showing special sensitivities to HMAs could be regarded as one of the ways to achieve a better prognosis. In 2017, we reported, although with an earlier relapse, patients with TP53 mutations could achieve a high CR rate to decitabine [19]. We then reported a high response (83.3%; 5/6 patients) to decitabine and 66 months of median RFS in NPM1\textsuperscript{MUT}DNMT3A\textsuperscript{WT} patients [28]. In this assay, we again defined a special higher decitabine-induced CR in 14 BCOR\textsuperscript{MUT} patients (CR up to 57.1%; \( p = 0.036 \)) and a much longer post-CR survival (40 months vs. 20 months; \( p = 0.036 \)) when compared to those without BCOR mutations. Taken together, the therapeutic efficiency of decitabine would be optimized if we choose MDS patients with TP53 mutations, NPM1\textsuperscript{MUT} PNMT3A\textsuperscript{WT}, or BCOR mutations as first-line candidates for the decitabine treatment protocol. Notably, longer post-CR survival of the eight patients who achieve CR came from the premise that 3 patients who accepted no addition treatment after decitabine had an induced CR. We considered this reaction style to be very important and proposed a new theory about the medication method for hypomethylating agents. Perhaps a duly stop time but not a continuous application of HMAs, which can maintain an optimal epigenetic regulation state, will be the best choice for some special patients who achieved CR.

From the finding in this assay, whether the special mutation locus (like P483L at exon 4) was resistant to decitabine, while coexistence of ASXL1 mutations resulted in a decitabine-induced response need to be examined in a study with a larger sample size to reach a conclusion.

**Conclusions**

BCOR mutations seemed to play a role mainly in MDS patients with normal chromosomes, and biogenetically emerging after the initial but before the transformation related mutations. Which predict tAML transformation and poor prognosis when HMAs intervening is lack. Whereas BCOR\textsuperscript{MUT} MDS patients showed a sensitive response to the decitabine treatment protocol and achieved longer post-CR survival.

**Abbreviations**

BCOR: BCL6 corepressor; MDS: Myelodysplastic syndrome; HMA: Hypomethylating agents; NC: Normal chromosome; RAEB: Refractory anemia with excess blasts; PRC: Polycomb repressive complex; OS: Overall survival; FAB: French–American–British; IPSS: International prognostic scoring system; CMML: Chronic myelomonocytic leukemia; IWG: International working group; NGS: Next generation sequencing; AML: Acute myeloid leukemia; VAF: Variant allele frequency; TFS: Transformation-free survival; HI: Hematological improvement; CR: Complete remission.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13148-021-01157-8.

**Additional file 1: Figure S1.** Dynamics of BCOR and concurrence gene mutations before and after AML transformation in six MDS patients. The VAF of BCOR mutation and other concurrence gene mutations are showed in red and green bar, respectively. The black bar shows the AML transformation-related gene mutations. Table S1. Characteristics of 43 patients with myelodysplastic syndromes harboring BCOR mutations.

**Additional file 2.** RNA sequencing data of bone marrow mononuclear cells from three MDS patients with BCOR mutation and three patients with BCOR wild type.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

L.W. and X.L. designed the research and wrote the paper. X.L., L.W., C.C. and F.X. analyzed data, F.X., L.W., and C.C carried out the gene sequencing, Z.Z., J.G., Q.H., L.S., D.W., L.Z., J.S. and C.X. collected the clinical data. All authors read and approved the final manuscript.

**Funding**

This work was supported by the National Natural Science Foundation of China (81670121 and 81770120).
Availability of data and materials
The RNA sequencing dataset generated during the current study are available from the Additional file 2.

Declarations

Ethics approval and consent to participate
This study was approved by the Institutional Review Board/Ethical Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital.

Consent for publication
Not applicable.

Competing interests
There is no conflict of interest.

Received: 7 June 2021   Accepted: 23 August 2021
Published online: 30 August 2021

References

1. Issa JP. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood. 2013;121:3811–7.
2. Astolfi A, Fiore M, Melchionda F, Indio V, Bertuccio SN, Pession A. BCOR involvement in cancer. Epigenomics. 2019;11:835–55.
3. Kelly MJ, So J, Rogers AJ, Gregory G, Li J, Zethoven M, et al. Bcr loss perturbs myeloid differentiation and promotes leukaemogenesis. Nat Commun. 2019;10:1347.
4. Papaemmanuil E, Cazzola M, Malcovati L, Vyas P, Bowen D, et al. Chronic Myeloid Disorders Working Group of the international cancer genome consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–95.
5. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–9.
6. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27.
7. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagea G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7.
8. Damm F, Cherains V, Nagata Y, Yoshida K, Scourtzic L, Okuno Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013;122:1169–77.
9. Terada K, Yamauchi H, Ueki T, Usuki K, Kobayashi Y, Tajiya K, et al. Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis. Genes Chromosomes Cancer. 2018;57:401–8.
10. Abuhadra N, Mukherjee S, Al-Issa K, Usuki K, Kobayashi Y, Tajiya K, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leuk Lymphoma. 2019;60:1587–90.
11. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.
12. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25.
13. Esfeld A-K, Mrózek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, et al. The mutational oncprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017;31:2211–8.
14. Bolli N, Manes N, McKerrell T, Chi J, Park N, Gundem G, et al. Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. Haematologica. 2015;100:214–22.
15. Grossmann V, Tacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011;118:6153–63.
16. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.
17. Xu F, Zhu Y, He Q, Wu LY, Zhang Z, Shi WH, et al. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. J Transl Med. 2016;14:66.
18. Xu F, Zhu Y, He Q, Wu LY, Zhang Z, Shi WH, et al. Identification of micro RNA-regulated pathways using an integration of microRNA-mRNA microarray and bioinformatics analysis in CD34+ cells of myelodysplastic syndromes. Sci Rep. 2016;6:32232.
19. Chang C, Zhao Y, Xu E, Guo L, Zhang Z, He Q, et al. TPS3 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol. 2017;176:600–8.
20. Cao Q, Gearhart MD, Gery S, Shojaei S, Yang H, Sun H, et al. BCOR regulates myeloid cell proliferation and differentiation. Leukemia. 2016;30:1155–65.
21. Zeidan AM, Kharfan-Dabaja NA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol. 2014;21:123–30.
22. Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsiev NA, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131:118–21.
23. Jabbour E, Garcia-Manero G, Batty N, Shan J, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116:3830–4.
24. Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3222–7.
25. Bewersdorf JP, Zeidan AM. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? Expert Rev Hematol. 2020;13:1311–42.
26. Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019;6:e194-203.
27. Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4:2866–70.
28. Wu L, Li X, Xu F, Wu D, He Q, Song L, et al. NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy. Br J Haematol. 2020;189(5):962–4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.